Review Article
Tijani Abiola Tajudeen1*, Olaitan Lateefat Salam2, Idowu Afeez Temitope3, Abdulhakeem Idris Abdulhakeem4, Ishola Jonathan Adekunle5, Musa Ojeba Innocent6, Mustapha Abdulsalam7
1Department of Soil Science, Federal University of Technology, Minna, Nigeria.
2Department of Chemistry and Molecular Biology, University of Gothenburg, Sweden.
3Department of Medicinal Research, Kaohsiung Medical University Hospital, Taiwan.
4Department of Biodiversity and Bioresources, Al-Farabi Kazakh National University, Kazakhstan.
5Department of Public Health, Obafemi Awolowo University, Ile-Ife, Nigeria.
6,7Department of Microbiology, Skyline University, Nigeria.
*Corresponding Author: tijaniabiolat@gmail.com
DOI: https://doi.org/10.55006/biolsciences.2025.5305
Received: 15-12-2024
Revised: 16-01-2025
Accepted: 01-08-2025
Online: 01-09-2025
The soil microbiome represents a valuable and largely untapped resource for drug discovery, containing a diverse array of microorganisms capable of producing bioactive compounds with significant therapeutic potential. This study examines the role of soil-derived microorganisms in the development of novel antimicrobial, anticancer, and other bioactive agents, highlighting the advancements made through high-throughput sequencing, metagenomics, and omics technologies. These approaches have significantly enhanced our ability to identify and characterize bioactive compounds within complex soil ecosystems. However, challenges such as culturing unculturable microorganisms, ensuring compound stability, and translating findings into clinical applications remain significant barriers. The study also explores the integration of computational tools, particularly machine learning and artificial intelligence, which have shown promise in accelerating the identification and optimization of bioactive compounds. Moreso, ethical considerations surrounding soil bioprospecting, including environmental impact and sustainable practices, are discussed as critical factors in ensuring responsible microbial resource exploration. With antimicrobial resistance becoming an increasingly urgent global health crisis, the potential of soil microbiomes as a source of novel therapeutics is more crucial than ever. However, the study emphasizes the need for continued advancements in metagenomics, synthetic biology, and drug delivery systems. It also advocates for greater interdisciplinary collaboration to overcome existing challenges and unlock the full potential of soil microbiomes for drug discovery.
Keywords: Soil microbiome, Antimicrobial resistance, Bioactive compounds, Metagenomics, Drug discovery
Soil microbiomes are among the most diverse ecosystems on Earth, comprising bacteria, fungi, actinomycetes, and archaea. These microorganisms produce an array of secondary metabolites that have evolved as chemical defenses in their natural environment. Such metabolites have played pivotal roles in the development of modern medicine, including antibiotics like penicillin, discovered from Penicillium notatum, and streptomycin, isolated from Streptomyces griseus. These discoveries highlight the immense potential of soil microbiomes in addressing pressing global health challenges (1). However, the vast majority of soil microorganisms remain unexplored due to their resistance to traditional cultivation techniques. Advances in metagenomic sequencing, high-throughput technologies, and computational tools have opened new frontiers in identifying and characterizing the metabolic potential of these uncultivable microorganisms. These advancements suggest that soil microbiomes remain an underutilized resource in the search for novel bioactive compounds (2).
Antimicrobial resistance (AMR) is an escalating crisis that poses a significant threat to global public health. It is projected that, by 2050, AMR could cause more deaths annually than cancer, leading to catastrophic health and economic consequences (World Health Organization, 2019). The misuse and overuse of antibiotics in both clinical and agricultural settings have accelerated the evolution of resistant pathogens, resulting in treatment failures and prolonged illnesses. Pathogens such as methicillin-resistant Staphylococcus aureus and carbapenem-resistant Enterobacteriaceae are increasingly rendering first-line antibiotics ineffective. Compounding the issue is the stagnation in antibiotic development, with only a few new drugs entering the market in recent decades. Soil microbiomes, with their vast and largely untapped reservoir of genetic and metabolic diversity, offer a promising solution to this global health challenge. They have the potential to yield novel antimicrobial compounds that can circumvent existing resistance mechanisms (3).
This study aims to explore the untapped potential of soil microbiomes in drug discovery, particularly in addressing antimicrobial resistance. The objectives of the study are threefold:
By synthesizing recent findings and methodologies, this review provides insights into how soil microbiomes can address the antimicrobial resistance crisis. Furthermore, it highlights ethical and technical challenges in soil bioprospecting and underscores the importance of interdisciplinary collaboration among microbiologists, computational biologists, and pharmacologists to harness the full potential of soil ecosystems.
Soil ecosystems are among the most biologically diverse habitats on Earth, supporting a vast array of microorganisms, including bacteria, fungi, actinomycetes, archaea, and viruses. A single gram of soil is estimated to harbor billions of microbial cells and thousands of distinct species, making it a critical reservoir of genetic and metabolic diversity. This diversity arises from the heterogeneous nature of soil, where variations in pH, moisture, nutrient availability, and organic matter create microhabitats conducive to microbial specialization and evolution (4). Among soil microorganisms, actinomycetes are particularly noteworthy for their prolific production of bioactive compounds, including antibiotics, antifungals, antivirals, and immunosuppressants. For instance, members of the Streptomyces genus have contributed to the discovery of over two-thirds of clinically important antibiotics, such as streptomycin, tetracycline, and erythromycin. Fungi, such as Penicillium and Aspergillus species, have also been instrumental in the development of drugs like penicillin and statins. This extraordinary microbial diversity underscores the soil microbiome's potential as a source for novel therapeutic agents (5). Advances in molecular biology and sequencing technologies have revealed that the vast majority of soil microorganisms remain unculturable under laboratory conditions, limiting their study through traditional microbiological methods. Metagenomics and other culture-independent approaches have enabled the characterization of these uncultivable microorganisms, revealing an even greater diversity of genes and metabolic pathways than previously imagined. This uncharted microbial diversity represents a largely untapped resource for drug discovery.
Soil microorganisms produce secondary metabolites as part of their natural survival strategies. These bioactive compounds are typically synthesized through specialized metabolic pathways that are distinct from primary metabolic processes like growth and reproduction. Secondary metabolites play key ecological roles, including chemical defense against competing microorganisms, communication, and adaptation to environmental stresses. The biosynthesis of secondary metabolites is encoded by clusters of genes known as biosynthetic gene clusters (BGCs). These clusters direct the production of structurally diverse and biologically active molecules, including polyketides, non-ribosomal peptides, alkaloids, and terpenoids. For example, the polyketide synthase pathway is responsible for the synthesis of macrolides like erythromycin, while non-ribosomal peptide synthetases produce antibiotics such as vancomycin (6). Recent advances in computational biology and bioinformatics have facilitated the identification and annotation of BGCs within microbial genomes. Tools like AntiSMASH and PRISM enable researchers to predict the biosynthetic potential of soil microorganisms by analyzing their genomic data. Further, metagenomic sequencing of soil samples has uncovered numerous cryptic BGCs—gene clusters that are not expressed under standard laboratory conditions but may be activated under specific environmental stimuli. These cryptic pathways represent a promising avenue for the discovery of novel bioactive compounds (7). The integration of omics technologies, such as transcriptomics, metabolomics, and proteomics, has further expanded our understanding of the metabolic potential of soil microorganisms. By linking genetic information to functional outputs, these approaches have facilitated the discovery of new natural products and elucidated their biosynthetic pathways. This integrated approach holds great promise for unlocking the full potential of soil microbiomes as a source of next-generation therapeutics.
Antimicrobial resistance (AMR) has emerged as a critical global health challenge, threatening the effectiveness of antibiotics that have been the cornerstone of modern medicine for decades. The World Health Organization (WHO) has identified AMR as one of the top ten global public health threats facing humanity. Common pathogens, including Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Mycobacterium tuberculosis, have developed resistance to multiple drugs, rendering infections caused by these organisms increasingly difficult to treat. This phenomenon has escalated mortality rates, prolonged hospital stays, and significantly increased healthcare costs worldwide (World Health Organization, 2019). The widespread misuse of antibiotics in clinical, agricultural, and veterinary settings has been a major driver of AMR. Antibiotics are often overprescribed in human medicine, and sub-therapeutic doses are commonly administered in animal husbandry to promote growth and prevent disease. These practices accelerate the selection pressure on microbial populations, facilitating the emergence of resistant strains. Consequently, previously manageable infections, such as those caused by Neisseria gonorrhoeae or Pseudomonas aeruginosa, are now associated with high treatment failure rates (8). Beyond the immediate clinical implications, AMR poses a severe threat to critical medical procedures. Surgeries, organ transplants, and cancer chemotherapy rely on effective antibiotics to prevent and treat infections. Without novel therapeutics to counteract resistance, these medical interventions are at significant risk, potentially leading to an era reminiscent of pre-antibiotic times when simple infections were often fatal.
The current arsenal of antibiotics is increasingly inadequate to combat the growing threat of resistant pathogens. Many of the antibiotics in use today were developed over 50 years ago, and few genuinely novel classes of antibiotics have been introduced since then. This stagnation is attributed to scientific, regulatory, and economic challenges in antibiotic development. The discovery of new antibiotics often involves high costs, lengthy development timelines, and uncertain financial returns due to the short-term use of antibiotics compared to chronic treatments (9). Moreover, the efficacy of existing antimicrobials is rapidly declining due to resistance mechanisms employed by pathogens. These mechanisms include enzymatic degradation of antibiotics, such as the production of beta-lactamases that inactivate penicillins and cephalosporins, and efflux pumps that expel antibiotics from bacterial cells. Other mechanisms include target modification, as seen with vancomycin-resistant Enterococcus species, and the development of biofilms, which provide a physical barrier against antibiotics. Combination therapies and the modification of existing antibiotics have been used as stopgap measures to extend the lifespan of current drugs. However, these strategies are not sustainable in the long term. For instance, while carbapenem-resistant Enterobacteriaceae can sometimes be treated with last-resort drugs like colistin, resistance to colistin has also been documented, leaving clinicians with few or no treatment options in such cases (10). The limitations of existing antimicrobials highlight an urgent need for innovative approaches to drug discovery. Soil microbiomes, with their immense genetic and metabolic diversity, present a promising avenue for identifying novel compounds that can bypass existing resistance mechanisms and target pathogens in unique ways. Harnessing this potential requires integrating traditional microbiological methods with advanced genomic and computational tools to unlock new therapeutic possibilities.
High-throughput sequencing (HTS) technologies have revolutionized our understanding of soil microbiomes by enabling the comprehensive analysis of microbial communities and their functional potential. Traditional culture-based methods for isolating soil microorganisms are limited by the inability to grow a large proportion of microbial species in the laboratory. HTS, particularly 16S rRNA gene sequencing for bacterial communities and ITS sequencing for fungi, bypasses this limitation by providing direct access to the genetic material of all soil microorganisms, including unculturable ones (11). The advent of next-generation sequencing (NGS) platforms, such as Illumina, PacBio, and Oxford Nanopore, has facilitated large-scale, cost-effective sequencing of microbial DNA. These platforms generate vast amounts of data, enabling the detection of microbial species that were previously unknown or understudied. NGS also allows for the sequencing of entire soil metagenomes, offering insights into the diversity of microbial genes involved in key ecological processes, including antibiotic production. The ability to sequence the genomes of microbial communities directly from soil samples has been instrumental in uncovering the biosynthetic potential of soil microorganisms, including previously cryptic biosynthetic gene clusters (BGCs) that can lead to the discovery of novel bioactive compounds (12). Moreover, the development of long-read sequencing technologies, such as Pacific Biosciences and Oxford Nanopore, has improved our ability to sequence complex genomes and accurately resolve long DNA sequences, enabling more detailed characterization of soil microbiomes and their functional capabilities (13). These advancements are crucial for studying soil microbiomes as sources of novel natural products for drug discovery.
Omics technologies are integral to modern microbiome research, providing deep insights into the functional capacities of soil microbial communities. Each omics approach—metagenomics, metabolomics, and proteomics—offers distinct advantages in profiling microbial functions, metabolic products, and cellular activities.
Together, these omics approaches enable the identification of novel bioactive compounds and the characterization of the metabolic pathways involved in their production, offering new opportunities for antimicrobial drug discovery.
Recent advancements in computational biology have significantly enhanced our ability to predict and analyze the biosynthetic pathways involved in the production of bioactive compounds by soil microorganisms. One of the key challenges in natural product discovery is identifying and characterizing the biosynthetic gene clusters (BGCs) responsible for the production of bioactive metabolites. While sequencing technologies have made it possible to detect these gene clusters, predicting their functions and understanding their regulatory mechanisms remain complex tasks.
Emerging computational tools have been developed to address these challenges. For instance, AntiSMASH (Antibiotic Synthethase Modeling and Analysis) is a widely used tool that can predict and annotate biosynthetic gene clusters in microbial genomes. By analyzing DNA sequences, AntiSMASH identifies known and novel BGCs, including those responsible for the synthesis of antibiotics, antifungals, and other bioactive compounds (17). Another computational tool, PRISM, enables the prediction of BGCs that synthesize non-ribosomal peptides, polyketides, and terpenes, all of which are key classes of bioactive molecules (18). Furthermore, advances in artificial intelligence (AI) and machine learning (ML) have paved the way for more accurate predictions of novel biosynthetic pathways. These AI-driven tools can analyze large datasets generated from metagenomic, metabolomic, and genomic data to identify potential biosynthetic pathways that were previously difficult to detect. Such innovations promise to accelerate the discovery of novel compounds from soil microbiomes and provide deeper insights into the biosynthetic capabilities of previously unexplored microorganisms (19).
Figure 1 outlines the major elements contributing to advancements in soil microbiome research. It focuses on high-throughput sequencing for exploring microbial diversity, omics approaches (metagenomics, metabolomics, and proteomics) for functional insights, and computational tools for biosynthetic pathway prediction. These components collectively drive innovation in antimicrobial discovery and ecological studies.
Figure 1. Advances in soil microbiome research: simplified framework.
Soil microbiomes have long been recognized as a rich source of natural products with potent biological activities, yet the exploration of soil-derived microorganisms for drug discovery remains limited. The vast majority of antibiotics and other therapeutic agents currently in use are derived from a small number of microbial species, such as Streptomyces and Penicillium. While these microorganisms have historically provided numerous valuable compounds, the microbial diversity in soil ecosystems far exceeds what has been fully explored (20). Soil contains a complex and largely untapped reservoir of microorganisms, including bacteria, fungi, and actinomycetes, that are capable of producing novel bioactive compounds. Many of these microorganisms remain unculturable, and thus their potential for natural product discovery is vastly underexploited.
This gap in exploration is partly due to the technical challenges associated with culturing soil microbes, as many soil microorganisms are not easily cultured in laboratory conditions. This issue is compounded by the fact that many bioactive compounds produced by soil microorganisms are not expressed under standard laboratory conditions. Therefore, many promising drug candidates remain undiscovered due to the inability to culture these microorganisms or to induce the production of their secondary metabolites (21). Moreover, the rapid advancement in sequencing technologies, such as metagenomics, has revealed the vast genetic potential of soil microbiomes, further highlighting the need for a more comprehensive exploration of these environments (22). However, there is a significant gap in translating this genetic information into practical applications for drug discovery.
The current pace of drug discovery from soil microbiomes is hampered by the underutilization of integrative computational and experimental techniques. While the advancement of sequencing technologies, such as next-generation sequencing (NGS), has provided an invaluable resource for profiling microbial communities in soil, this information often remains underexploited. The integration of omics data (metagenomics, metabolomics, and proteomics) with computational tools for biosynthetic pathway prediction is still in its infancy. As a result, many of the bioactive compounds predicted by genomic and metagenomic analyses are not experimentally validated or isolated (23).
One key challenge is the lack of effective methods to predict the function of novel biosynthetic gene clusters (BGCs) found in soil metagenomes. While tools like AntiSMASH and PRISM have made significant strides in predicting BGCs, translating these predictions into experimentally verified natural products remains a bottleneck. The gap lies in the ability to use computational predictions to guide laboratory efforts in synthesizing or isolating these bioactive compounds. The integration of computational predictions with high-throughput screening technologies, as well as systems biology approaches, could enable researchers to rapidly identify and characterize novel compounds with therapeutic potential (24). Moreover, the use of artificial intelligence (AI) and machine learning (ML) tools in drug discovery from soil microbiomes has shown promise in predicting the structure and activity of new natural products. However, their application in microbiome research is still limited and largely experimental, indicating a gap in fully harnessing the power of AI and ML in identifying novel drug candidates (25). Combining AI-driven predictions with targeted experimental validation could bridge this gap and lead to more efficient discovery pipelines for bioactive compounds.
Sustainable bioprospecting methods are critical for ensuring that drug discovery efforts from soil microbiomes do not result in long-term ecological damage. Traditional bioprospecting approaches often involve the indiscriminate collection of soil samples and the destruction of microbial habitats. These methods, while effective in some cases, pose a risk to biodiversity and soil ecosystems, especially as the demand for novel natural products increases. The overharvesting of certain microorganisms from natural environments can lead to the depletion of microbial populations, disrupting ecological balance and diminishing the potential for future drug discovery (26). There is a growing need for more sustainable approaches to bioprospecting that prioritize the conservation of microbial diversity while still enabling the discovery of novel therapeutic agents. One promising approach is the use of metagenomic techniques, which allow for the analysis of soil microbiomes without the need for traditional cultivation. By sequencing the DNA of microbial communities directly from soil samples, researchers can access the genetic potential of unculturable microorganisms without disturbing their natural habitats. Moreover, advances in synthetic biology and bioreactor technology could facilitate the large-scale cultivation of microorganisms in controlled environments, reducing the need to collect soil samples from the wild (27). Moreso, the integration of sustainable practices into bioprospecting, such as the development of microbial resource management plans and the promotion of microbial conservation efforts, is critical for maintaining the integrity of soil ecosystems. Ensuring that bioprospecting efforts are environmentally responsible and do not lead to the loss of microbial diversity is vital for the long-term sustainability of drug discovery from soil microbiomes.
Metagenomics has revolutionized the study of microbial communities by allowing direct analysis of the genetic material found in environmental samples, including soil. This technique eliminates the need for culturing microorganisms and opens up the possibility of discovering novel bioactive compounds produced by unculturable or previously unknown microbes. The soil microbiome is highly diverse, with an estimated 1,000 species of bacteria, fungi, and actinomycetes per gram of soil, many of which have the potential to produce bioactive secondary metabolites (28). By sequencing soil DNA and analyzing metagenomic libraries, researchers can identify genes involved in the biosynthesis of bioactive compounds. This approach has already yielded significant results in natural product discovery. For example, metagenomic mining has led to the identification of previously overlooked biosynthetic gene clusters (BGCs) that are responsible for the production of antibiotics, anticancer agents, and other therapeutics. These BGCs can be further analyzed to predict their metabolic pathways and to identify potential drug candidates (29). Moreso, the use of metagenomic sequencing allows researchers to explore microbial communities from diverse environments, increasing the likelihood of discovering novel compounds with therapeutic activity. This approach can be paired with high-throughput screening (HTS) to identify bioactive compounds in soil samples that match the genomic sequences found in metagenomic data, bridging the gap between genomic data and the discovery of tangible, usable therapeutics (30). Thus, leveraging metagenomics provides an effective strategy for unlocking the full drug discovery potential of soil microbiomes.
Machine learning (ML) has gained considerable traction in drug discovery due to its ability to handle and analyze large datasets quickly and efficiently. In the context of soil microbiomes, ML can play a key role in predictive compound screening by analyzing the genomic and chemical data derived from metagenomic, metabolomic, and proteomic studies. Through supervised and unsupervised learning models, ML algorithms can predict the bioactivity of compounds based on their molecular features, such as structure, chemical properties, and genetic origin (31). For instance, ML algorithms can be used to predict the antimicrobial properties of novel compounds based on genomic sequences and previously known antimicrobial molecules. This approach can significantly reduce the time and resources spent on screening large chemical libraries in the lab. ML models can also be trained to identify potential therapeutic candidates from complex datasets by finding patterns that may not be immediately apparent to human researchers. Recent studies have demonstrated the power of ML models in predicting the antimicrobial activity of natural products derived from soil microbiomes (32). Moreover, ML can be applied to optimize the bioprocessing of soil-derived microorganisms for drug production. By analyzing data from bioreactor systems, ML models can predict the conditions under which microbial cultures will produce the highest yield of bioactive compounds, thus improving the efficiency of biotechnological drug production. Integrating ML with computational tools for biosynthetic pathway prediction (e.g., AntiSMASH, PRISM) further enhances its utility by enabling researchers to focus on the most promising natural product candidates for experimental validation (33). This combination of ML with omics and computational tools offers a powerful strategy for accelerating drug discovery from soil microbiomes.
Addressing the research gap in soil microbiome-based drug discovery requires an interdisciplinary approach that combines the strengths of microbiology, computational biology, and pharmacology. Microbiologists can provide essential insights into the ecology of soil microbiomes, identifying which microbial species or communities are most likely to produce bioactive compounds. By utilizing traditional and molecular microbiology techniques, such as culture-based methods and DNA sequencing, they can characterize microbial diversity and pinpoint organisms of interest for drug discovery (34). Computational biology is crucial for handling the vast amount of data generated by sequencing technologies. Through bioinformatics and computational tools, such as genome-wide association studies (GWAS) and pathway prediction software, computational biologists can analyze genomic data to predict biosynthetic gene clusters and metabolic pathways involved in compound production. They also employ advanced algorithms to analyze large datasets from metagenomics, metabolomics, and proteomics, extracting meaningful patterns that can guide drug discovery efforts (35). Pharmacologists and drug development experts play a critical role in evaluating the therapeutic potential of the compounds identified through microbiological and computational research. They are involved in screening compounds for biological activity, assessing their pharmacokinetic properties, and conducting preclinical studies to evaluate safety and efficacy. Collaborations between pharmacologists and computational biologists also facilitate the development of predictive models for drug efficacy, helping to identify the most promising candidates for clinical trials (36). A successful example of such collaboration is seen in the ongoing efforts to discover new antibiotics from soil microbiomes, where the combined expertise of microbiologists, computational biologists, and pharmacologists has led to the identification of new classes of antimicrobial agents with potential for treating drug-resistant infections (37). These interdisciplinary collaborations not only enable a more holistic approach to drug discovery but also speed up the process of bringing novel therapeutics to market. Figure 2 below provides a simplified overview of key strategies for advancing soil microbiome-based drug discovery. It focuses on Leveraging Metagenomics, Machine Learning, and Interdisciplinary Collaborations to bridge research gaps. Metagenomics identifies bioactive compounds, machine learning accelerates predictive screening, and interdisciplinary collaboration integrates microbiology, computational biology, and pharmacology to optimize therapeutic outcomes. Together, these strategies facilitate the discovery of novel, sustainable therapeutics.
Figure 2. Strategies to address the research gap in soil microbiome-based drug discovery.
Soil bioprospecting, the practice of searching for valuable bioactive compounds within soil microbiomes, has become a promising avenue for drug discovery. However, there are several technical and ethical challenges associated with this approach that need to be addressed for the sustainable and effective use of soil microorganisms in drug development.
From a technical standpoint, one of the major challenges is the difficulty in culturing soil microorganisms. Many of the microbes that could potentially produce novel bioactive compounds are not readily cultivable under standard laboratory conditions, limiting the exploration of their therapeutic potential. Advances in metagenomics and other high-throughput techniques have enabled the direct sequencing of microbial DNA from environmental samples, bypassing the need for culturing. However, even with these technologies, translating genomic data into practical applications remains challenging (38). The identification of biosynthetic gene clusters (BGCs) from soil microbiomes, while promising, often lacks the ability to induce the expression of secondary metabolites in vitro, as many bioactive compounds are produced under specific environmental conditions or when microbes are exposed to stress (39). Overcoming these technical limitations will require more advanced culturing techniques, enhanced bioinformatics tools, and better methods to induce the production of bioactive compounds in laboratory settings.
Ethically, soil bioprospecting raises concerns about the conservation of microbial biodiversity and the environmental impact of collecting soil samples. The indiscriminate collection of soil samples from natural habitats can deplete microbial populations and disrupt ecosystems, potentially leading to the loss of valuable genetic resources. This risk is particularly high in biodiversity hotspots, where microbial diversity is critical to maintaining ecological balance. Therefore, there is an urgent need to establish guidelines for sustainable bioprospecting that ensure minimal environmental disruption and prioritize the conservation of microbial diversity (40). Furthermore, the use of soil samples from indigenous lands or protected areas poses additional ethical concerns related to the rights of local communities and the fair distribution of the benefits derived from natural products. The ethical issues surrounding bioprospecting necessitate the development of policies that protect both the environment and the interests of local communities while ensuring that the benefits of drug discovery are shared equitably.
Despite the promising discovery of bioactive compounds through soil bioprospecting, translating these compounds into clinically viable drugs is fraught with challenges. Even after identifying a promising compound, the process of bringing it from the laboratory bench to clinical use is long, complex, and expensive. Many of the compounds discovered through microbiome research exhibit potent bioactivity in laboratory settings, but their clinical development faces significant hurdles. A major challenge is the issue of compound stability and bioavailability. Many naturally derived compounds from soil microorganisms, particularly antibiotics and anticancer agents, are often unstable or difficult to synthesize in large quantities. Furthermore, some bioactive compounds are poorly absorbed by the human body, limiting their therapeutic effectiveness. To address this, researchers must explore ways to optimize the pharmacokinetic properties of these compounds, such as improving their solubility, stability, and absorption rates. This can be achieved through chemical modifications or by developing new drug delivery systems that enhance the bioavailability of the compounds (41).
Moreso, clinical trials are a critical step in evaluating the safety and efficacy of new compounds. Natural products derived from soil microorganisms often require rigorous testing to determine their safety profiles, potential side effects, and optimal dosages. While some compounds may show promise in preclinical trials, many fail during human clinical trials due to toxicity, adverse effects, or insufficient therapeutic benefits. Thus, the translation of identified compounds into clinically approved drugs is a lengthy and expensive process that requires substantial investment and resources. Moreover, regulatory issues can impede the progress of natural product drug development. The approval process for new drugs is highly regulated and requires extensive documentation of a compound's safety, efficacy, and manufacturing processes. Natural products, especially those derived from novel or uncharacterized sources, may face additional regulatory scrutiny, further delaying their potential clinical use.
Soil microbiome research holds immense promise for future drug discovery, especially in the context of antibiotic resistance and the search for new therapeutic agents. Moving forward, several key areas of research are likely to shape the future of soil microbiome-based drug discovery.
One promising direction is the continued use and refinement of metagenomic techniques to discover new bioactive compounds. As sequencing technologies become more advanced and cost-effective, researchers will be able to profile soil microbial communities at a much higher resolution, enabling the identification of new biosynthetic pathways and previously overlooked bioactive compounds (42). The development of new metagenomic tools, such as CRISPR-Cas-based techniques for gene editing, will further accelerate the process of isolating and studying bioactive compounds from unculturable microorganisms. Another important area of research is the integration of synthetic biology and metabolic engineering. By combining knowledge of soil microbial communities with cutting-edge genetic engineering techniques, researchers will be able to design and produce novel compounds that are not only bioactive but also commercially viable. For example, synthetic biology could enable the production of complex natural products in lab-grown microorganisms, reducing the need for extensive bioprospecting and improving the scalability of drug production (43).
Advancements in artificial intelligence (AI) and machine learning (ML) will also play a significant role in shaping future soil microbiome research. AI and ML algorithms can process vast amounts of data generated by omics techniques, helping to predict the bioactivity of novel compounds, identify potential drug candidates, and optimize biosynthetic pathways for large-scale production. These tools will also help to identify novel target sites for therapeutic intervention, enhancing the drug discovery process (Finally, the future of soil microbiome research will also depend on fostering greater collaboration between researchers across multiple disciplines, including microbiology, computational biology, pharmacology, and environmental science. By working together, these diverse fields can address the technical, ethical, and regulatory challenges associated with soil bioprospecting and drug development. Collaborative efforts will lead to more sustainable and effective methods for exploring soil microbiomes and translating these discoveries into clinical therapies.
This study highlights the immense potential of soil microbiomes as a rich source of bioactive compounds for drug discovery. The diversity of microorganisms in soil ecosystems offers a promising reservoir of novel therapeutic agents, particularly in the context of addressing the global challenge of antimicrobial resistance. Advances in high-throughput sequencing, metagenomics, and other omics technologies have revolutionized our ability to explore these microbiomes and identify microbial species that produce bioactive compounds with antimicrobial, anticancer, and other medicinal properties. Despite significant progress, several technical and ethical challenges remain, particularly in the culturing of microorganisms, the stability of compounds, and ensuring sustainable bioprospecting practices. This study contributes to the scientific community by providing a comprehensive overview of the current state of soil microbiome research in drug discovery, emphasizing the importance of integrating microbiology, computational biology, and pharmacology. By discussing both the successes and limitations in this field, the study serves as a valuable resource for researchers looking to explore novel therapeutic compounds from soil-derived microorganisms. It also underscores the need for interdisciplinary collaboration, as the convergence of different scientific fields is essential for overcoming challenges such as compound stability and bioavailability, as well as accelerating the translation of bioactive compounds into clinically viable drugs. Looking ahead, there is a clear need for continued innovation in both experimental techniques and computational tools to unlock the full potential of soil microbiomes for drug discovery. Future research should focus on refining metagenomic approaches and synthetic biology techniques to enable the cultivation and production of previously unculturable microorganisms and their bioactive compounds.
The authors would like to express their sincere gratitude to Professor (Mrs) R. N Ahmed, former Head of the Department of Microbiology, Faculty of Life Sciences, University of Ilorin, Nigeria, for her invaluable guidance, expert advice, and unwavering support throughout the research process. Her mentorship has been instrumental in shaping the direction of the study.
The authors declare no conflicts of interest.
The research received no funding from any source.
Not available.
Tajudeen TA, Salam OL, Temitope IA, Abdulhakeem AI, Adekunle IJ, Innocent MO, et al. Exploration of Soil Microbiomes as a Source of Novel Antimicrobial Compounds for Combating Drug-Resistant Pathogens. Biol. Sci. 2025, 5(3):1005-1017.
Published by IR Research Publication | © 2025 Authors | Licensed under CC BY 4.0 | ISSN: 2583-1399 | Volume 5, Issue 3 | Page 1005-1017